Navigation Links
Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors
Date:4/16/2009

BONITA SPRINGS, Fla., April 16 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held company developing targeted cancer treatment therapies, today announced the appointment of Pedro Granadillo as Chairman of the company's Board of Directors. Mr. Granadillo is a highly-respected pharmaceutical industry leader with over 30 years of experience in corporate management.

"Pedro's appointment as Chairman of the Board of Directors will further expand his leadership role within our company and will play a key role in our partnering efforts and corporate strategy. We are pleased to have such a widely respected and experienced senior pharmaceutical executive chair our Board of Directors," said Edmundo Muniz, Chief Executive Officer of Tigris. "His past experience and proven track record in pharmaceutical drug development will be instrumental as we drive our partnering programs and our clinical programs forward."

"I am excited to be serving as Chairman at this important time in the Company's development," said Mr. Granadillo. "I look forward to working with the management team, the Board and the Company's investors in implementing the Company's strategic initiatives over the next year and beyond."

Mr. Granadillo served as Senior Vice President for Eli Lilly and Company until his retirement in 2004 after 34 years of service. As a member of Lilly's Executive Committee and as Lilly's head of human resources, manufacturing and quality, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly's conventional "small-molecule" pharmaceuticals and "large-molecule" biotech therapies.

Mr. Granadillo also currently serves on the boards of directors of Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Nile Therapeutics, San Francisco, CA. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies, using a translational research approach, for use in oncology and other areas of unmet medical need. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. All statements, other than statements of historical facts, including statements regarding Tigris' strategy, future operations, outlook, and plans and objectives of management, are forward-looking statements. We may not actually achieve these plans, intentions or expectations. Various important factors could cause actual results or events to differ materially from these forward-looking statements, including among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our collaborators' ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. This information is provided as of the date of this press release and Tigris does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
2. Vion Pharmaceuticals New Drug Application for Onrigin(TM)Accepted For Review by the FDA
3. Generic Pharmaceuticals Offer Exciting Growth Opportunities in Tanzania, Reveals Frost & Sullivan
4. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
5. Amylin Pharmaceuticals to Webcast First Quarter Results
6. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
7. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
8. Sigma-Tau Pharmaceuticals and Danisco BioActives Announce Partnership Agreement to Develop Drug Candidate for Prevention of Necrotizing Enterocolitis
9. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
10. Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
11. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon ... cyber threats in real-time, today announced a strategic partnership with TechLab Security, ... Joining other Seceon partners, TechLab Security has become a strategic partner and a ...
(Date:1/17/2017)... Torrance, CA (PRWEB) , ... January 17, 2017 , ... Many people make New Year’s ... Dr. Robert Mondavi is making it easier for people who want to kick ... for both new and existing patients. , These special offers include: , ...
(Date:1/16/2017)... ... 2017 , ... Recently, patients and staff from A Forever Recovery, a holistic ... in support of the annual Binder Park Zoo Halloween celebration known as the “Zoo ... of all designs coming out to enjoy games, face painting, and lots and lots ...
(Date:1/16/2017)... Lake, Utah (PRWEB) , ... January 16, 2017 , ... ... (UAC) officially opened on January 8 for use by sports teams and the general ... full, indoor volleyball courts that can also be converted into basketball or pickleball courts. ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Ind. , Jan. 17, 2017  Zimmer Biomet ... in musculoskeletal healthcare , today announced that ... on the strength of the Zimmer Biomet management ... Delp will assume the position of President, ... the Company. Mr. Delp previously served as Zimmer Biomet,s ...
(Date:1/17/2017)... Research and Markets has announced the addition ... their offering. ... The global laparotomy sponges market to grow at a CAGR of ... Sponges Market 2016-2020, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:1/17/2017)... 17, 2017  Maureen L. Mulvihill, President and ... of 6 senior sales leaders to support the ... sales leaders were formerly part of the top ... Repeatedly recognized for their performance, they have a ... establishing relationships with key customer constituencies. "I ...
Breaking Medicine Technology: